

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISI	HED U	UNDER THE PATENT COOPERATION TREATY (PCT)
(51) International Patent Classification 7:		(11) International Publication Number: WO 00/34526
C12Q 1/68, C07K 14/435	A1	(43) International Publication Date: 15 June 2000 (15.06.00
21) International Application Number: PCT/US 22) International Filing Date: 10 December 1999 (		DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
30) Priority Data: 09/210,330 11 December 1998 (11.12.9)	8) l	Published With international search report.
71) Applicant: CLONTECH LABORATORIES, INC. 4020 East Meadow Drive, Palo Alto, CA 94303 (1		<b>3</b> ];
72) Inventors: LUKYANOY, Sergey Anatolievich; ulbinskaya 13/1-161, Moscow (RU). FRADKOV Fedorovich; ul. Dnepropetrovskaya, 35/2-14, 113570 (RU). LABAS, Yulii Aleksandrovich; erala Tyuleneva, 35-416, Moscow, 117465 (RU). Mikhail Vladimirovich; ul. Teplii stan, 7/2-28, 117465 (RU).	', Arca Mosco ul. Ge . MAT	dy w, on- Z,
74) Agent: ADLER, Benjamin, A.; McGregor & Adl Candle Ln., Houston, TX 77071 (US).	ler, 80	II .
•		
SUCH PROTEINS AND USES THEREOF  57) Abstract  The present invention is directed to novel fluorescer	nt prote	winescent species of class anthozoa, genes encoding the from non-bioluminescent organisms from the Class Anthozoa. All ing the fluorescent proteins and further analyzing the proteins.
		•
		•
•		

# FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ .	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	υG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	υz	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Vict Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	2W	Zimbabwe
a	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		٠.
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	u	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia .	SG	Singapore		

PCT/US99/29405

# FLUORESCENT PROTEINS FROM NON-BIOLUMINESCENT SPECIES OF CLASS ANTHOZOA, GENES ENCODING SUCH PROTEINS AND USES THEREOF

5

10

15

#### BACKGROUND OF THE INVENTION

#### Field of the Invention

This invention relates to the field of molecular biology. More specifically, this invention relates to novel fluorescent proteins, methods of identifying the DNA sequences encoding the proteins and uses thereof.

#### Description of the Related Art

Fluorescence labeling is a particularly useful tool for marking a protein, cell, or organism of interest. 20 Traditionally, a protein of interest is purified, then covalently conjugated fluorophore derivative. For in vivo studies, the protein-dye complex is then inserted into cells of interest using micropipetting or a method of The dye attachment and insertion steps, reversible permeabilization. however, make the process laborious and difficult to control. An 25 alternative method of labeling proteins of interest is to concatenate or fuse the gene expressing the protein of interest to a gene expressing a marker, then express the fusion product. Typical markers for this method of protein labeling include β-galactosidase, firefly luciferase

15

20

25

WO 00/34526 PCT/US99/29405

and bacterial luciferase. These markers, however, require exogenous substrates or cofactors and are therefore of limited use for in vivo studies.

A marker that does not require an exogenous cofactor or substrate is the green fluorescent protein (GFP) of the jellyfish Aequorea victoria, a protein with an excitation maximum at 395 nm, a second excitation peak at 475 nm and an emission maximum at 510 nm. GFP is a 238-amino acid protein, with amino acids 65-67 involved in the formation of the chromophore.

Uses of GFP for the study of gene expression and protein localization are discussed in detail by Chalfie et al. in Science 263 (1994), 802-805, and Heim et al. in Proc. Nat. Acad. Sci. 91 (1994), 12501-12504. Additionally, Rizzuto et al. in Curr. Biology 5 (1995), 635-642, discuss the use of wild-type GFP as a tool for visualizing subcellular organelles in cells, while Kaether and Gerdes in Febs Letters 369 (1995), 267-271, report the visualization of protein transport along the secretory pathway using wild-type GFP. The expression of GFP in plant cells is discussed by Hu and Cheng in Febs Letters 369 (1995), 331-334, while GFP expression in Drosophila embryos is described by Davis et al. in Dev. Biology 170 (1995), 726-729.

Crystallographic structures of wild-type GFP and the mutant GFP S65T reveal that the GFP tertiary structure resembles a barrel (Ormö et al., Science 273 (1996), 1392-1395; Yang, et al., Nature Biotechnol 14 (1996), 1246-1251). The barrel consists of beta sheets in a compact structure, where, in the center, an alpha helix containing the chromophore is shielded by the barrel. The compact structure makes GFP very stable under diverse and/or harsh conditions such as protease treatment, making GFP an extremely useful reporter in

15

20

WO 00/34526 PCT/US99/29405

general. However, the stability of GFP makes it sub-optimal for determining short-term or repetitive events.

A great deal of research is being performed to improve the properties of GFP and to produce GFP reagents useful and optimized for New versions of GFP have been a variety of research purposes. developed, such as a "humanized" GFP DNA, the protein product of which has increased synthesis in mammalian cells (Haas, et al., Current -Biology 6 (1996), 315-324; Yang, et al., Nucleic Acids Research 24 (1996), 4592-4593). One such humanized protein is "enhanced green fluorescent protein" (EGFP). Other mutations to GFP have resulted in blue-, cyan- and yellow-green light emitting versions. Despite the great utility of GFP, however, other fluorescent proteins with properties similar to or different from GFP would be useful in the art. fluorescent proteins result in possible new colors, or produce pHdependent fluorescence. Other benefits of novel fluorescent proteins include fluorescence resonance energy transfer (FRET) possibilities based on new spectra and better suitability for larger excitation.

The prior art is deficient in novel fluorescent proteins wherein the DNA coding sequences are known. The present invention fulfills this long-standing need in the art.

#### SUMMARY OF THE INVENTION

The present invention is directed to an isolated and purified fluorescent protein selected from the group consisting of amFP486, cFP484, zFP506, zFP538, dsFP483, drFP583, asFP600, dgFP512 and dmFP592.

15

25

WO 00/34526 PCT/US99/29405

In one embodiment of the present invention, there is provided a method of identifying a DNA sequence encoding a fluorescent protein comprising the step of screening for an existence of a nucleic acid sequence in a sample, wherein the nucleic acid sequence encodes a peptide having a sequence selected from the group consisting of SEQ ID Nos. 3, 5, 8, 11, 12 and 14. The existence of the nucleic acid sequence identifies the DNA sequence encoding the fluorescent protein.

In another embodiment of the present invention, there is provided a method of identifying a DNA sequence encoding a fluorescent protein comprising the step of screening for an existence of a nucleic acid sequence in a sample, wherein the nucleic acid sequence hybridizes to a primer selected from the group consisting of SEQ ID Nos. 4, 6, 7, 9, 10, 13, 15 and 16. The existence of the nucleic acid sequence identifies the DNA sequence encoding the fluorescent protein.

In still another embodiment of the present invention, there is provided a method of analyzing a fluorescent protein in a cell, comprising the steps of expressing a nucleic acid sequence encoding a fluorescent protein having an amino acid sequence selected from the group consisting of SEO ID Nos. 55-63 in the cell; and measuring a fluorescence signal from the protein. This method further comprises a step of sorting the cell according to the signal. Preferably, the cell is sorted by fluorescence activated cell sorting. Still preferably, the nucleic acid sequence comprises a gene of interest encoding a protein of interest fused to the fluorescent protein, wherein the protein of interest is distinct from the fluorescent protein. The detected fluorescence signal indicates the presence of the gene of interest and the protein of interest in the cell. By identifying an further

15

20

25

WO 00/34526 PCT/US99/29405

intracellular location of the fluorescent protein, an intracellular location of the protein of interest is also identified.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the modified strategy of 3'-RACE used to isolate the target fragments. Sequences of the oligonucleotides used are shown in Table 2. Dp1 and Dp2 are the degenerate primers used in the first and second PCR, respectively (see Tables 3 and 4 for the sequences of degenerate primers).

Figure 2A shows multiple alignment of novel fluorescent proteins. The numbering is based on Aequorea victoria green fluorescent protein (GFP). Two proteins from Zoanthus and four from Discosoma are compared between each other: residues identical to the corresponding ones in the first protein of the series are represented by dashes. Introduced gaps are represented by dots. In the sequence of A. victoria GFP, the stretches forming beta-sheets are underlined; the residues whose side chains form the interior of the beta-can are shaded (according to Yang et al., Nature Biotechnol. 14, 1246–1251 (1996). Figure 2B shows the N-terminal part of cFP484, which has no homology with the other proteins. The putative signal peptide is underlined.

Figure 3 shows the excitation and emission spectrum of the novel fluorescent protein from *Anemonia majano*, amFP486.

15

25

WO 00/34526

PCT/US99/29405

Figure 4 shows the excitation and emission spectrum of the novel fluorescent protein from *Clavularia*, cFP484.

Figure 5 shows the excitation and emission spectrum of the novel fluorescent protein from Zoanthus, zFP506.

Figure 6 shows the excitation and emission spectrum of the novel fluorescent protein from Zoanthus, zFP538.

Figure 7 shows the excitation and emission spectrum of the nevel fluorescent protein from *Discosoma striata*, dsFP483.

Figure 8 shows the excitation and emission spectrum of 10 the novel fluorescent protein from Discosoma, drFP583.

Figure 9 shows the excitation and emission spectrum of the novel fluorescent protein from Anemonia sulcata, asFP600.

Figure 10 shows the excitation and emission spectrum of the novel fluorescent protein from *Discosoma*, dgFP512.

Figure 11 shows the excitation and emission spectrum of the novel fluorescent protein from *Discosoma*, dmFP592.

#### DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term "GFP" refers to the basic green fluorescent protein from Aequorea victoria, including prior art versions of GFP engineered to provide greater fluorescence or fluoresce in different colors. The sequence of Aequorea victoria GFP (SEQ ID No. 54) has been disclosed in Prasher et al., Gene 111 (1992), 229-33.

As used herein, the term "EGFP" refers to mutant variant of GFP having two amino acid substitutions: F64L and S65T (Heim et al., Nature 373 (1995), 663-664). The term "humanized" refers to changes made to the GFP nucleic acid sequence to optimize the codons for

15

25

WO 00/34526 PCT/US99/29405

expression of the protein in human cells (Yang et al., Nucleic Acids Research 24 (1996), 4592-4593).

In accordance with the present invention there may be molecular microbiology, employed conventional biology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Maniatis, Fritsch & Sambrook, "Molecular Cloning: A Laboratory Manual (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" (B.D. Hames & S.J. Higgins eds. (1985)); "Transcription and Translation" (B.D. Hames & S.J. Higgins eds. (1984)); "Animal Cell Culture" (R.I. Freshney, ed. (1986)); "Immobilized Cells and Enzymes" (IRL Press, (1986)); B. Perbal, "A Practical Guide To Molecular Cloning" (1984).

A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.

A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in either single stranded form or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes.

A DNA "coding sequence" is a DNA sequence which is transcribed and translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3'

20

25

WO 00/34526 PCT/US99/29405

(carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and synthetic DNA sequences. A polyadenylation signal and transcription termination sequence may be located 3' to the coding sequence.

As used herein, the term "hybridization" refers to the process of association of two nucleic acid strands to form an antiparallel duplex stabilized by means of hydrogen bonding between residues of the opposite nucleic acid strands.

The term "oligonucleotide" refers to a short (under 100 bases in length) nucleic acid molecule.

"DNA regulatory sequences", as used herein, are transcriptional and translational control sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for and/or regulate expression of a coding sequence in a host cell.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements detectable necessary initiate transcription at levels above Within the promoter sequence will be found a background. initiation site, as well as protein binding transcription responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes. Various promoters, including inducible promoters, may be used to drive the various vectors of the present invention.

25

WO 00/34526

PCT/US99/29405

As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

A cell has been "transformed" or "transfected" exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth in vitro for many generations.

A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. In another example, heterologous DNA includes coding sequence in a construct where portions of genes from two different sources have been brought together so as to produce a fusion protein product. Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein.

15

20

WO 00/34526 PCT/US99/29405

As used herein, the term "reporter gene" refers to a coding sequence attached to heterologous promoter or enhancer elements and whose product may be assayed easily and quantifiably when the construct is introduced into tissues or cells.

The amino acids described herein are preferred to be in the "L" isomeric form. The amino acid sequences are given in one-letter code (A: alanine; C: cysteine; D: aspartic acid; E: gluetamic acid; F: phenylalanine; G: glycine; H: histidine; I: isoleucine; K: lysine; L: leucine; M: metionine; N: asparagine; P: proline; Q: gluetamine; R: arginine; S: serine; T: threonine; V: valine; W: tryptophane; Y: tyrosine; X: any residue). NH<sub>2</sub> refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. In keeping with standard polypeptide nomenclature, J Biol. Chem., 243 (1969), 3552-59 is used.

The present invention is directed to an isolated and purified fluorescent protein selected from the group consisting of amFP486, cFP484, zFP506, zFP538, dsFP483, drFP583, asFP600, dgFP512 and dmFP592.

In one embodiment of the present invention, there is provided a method of identifying a DNA sequence encoding a fluorescent protein comprising the step of screening for an existence of a nucleic acid sequence in a sample, wherein the nucleic acid sequence encodes a peptide having a sequence selected from the group consisting of SEQ ID Nos. 3, 5, 8, 11, 12 and 14. The existence of the nucleic acid sequence identifies the DNA sequence encoding the fluorescent protein.

In another embodiment of the present invention, there is provided a method of identifying a DNA sequence encoding a

15

20

WO 00/34526 PCT/US99/29405

fluorescent protein comprising the step of screening for an existence of a nucleic acid sequence in a sample, wherein the nucleic acid sequence hybridizes to a primer selected from the group consisting of SEQ ID Nos. 4, 6, 7, 9, 10, 13, 15 and 16. The existence of the nucleic acid sequence identifies the DNA sequence encoding the fluorescent protein.

In still another embodiment of the present invention, there is provided a method of analyzing a fluorescent protein in a cell, comprising the steps of expressing a nucleic acid sequence encoding a fluorescent protein having an amino acid sequence selected from the group consisting of SEQ ID Nos. 55-63 in the cell; and measuring a fluorescence signal from the protein. This method further comprises a step of sorting the cell according to the signal. Preferably, the cell is sorted by fluorescence activated cell sorting. Still preferably, the nucleic acid sequence comprises a gene of interest encoding a protein of interest fused to the fluorescent protein, wherein the protein of interest is distinct from the fluorescent protein. The detected fluorescence signal indicates the presence of the gene of interest and further the protein of interest in the cell. By identifying an intracellular location of the fluorescent protein, an intracellular location of the protein of interest is also identified.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

PCT/US99/29405

#### EXAMPLE 1

# Biological Material

Novel fluorescent proteins were identified from several genera of Anthozoa which do not exhibit any bioluminescence but have fluorescent color as observed under usual white light or ultraviolet light. Six species were chosen (see Table 1).

10

5

#### TABLE 1

# Anthozoa Species Used in This Study

Species	Area of Origination	Fluorescent Color
Anemonia	Western Pacific	bright green tentacle tips
majano		
Clavularia sp.	Western Pacific	bright green tentacles and
		oral disk
Zoanthus sp.	Western Pacific	green-yellow tentacles and
		oral disk
Discosoma sp.	Western Pacific	orange-red spots oral disk
"red"		
Discosoma	Western Pacific	blue-green stripes on oral
striata		disk
Discosoma sp.	Western Pacific	faintly purple oral disk
"magenta"		
Discosoma sp.	Western Pacific	green spots on oral disk
Discosoma sp.  "red"  Discosoma striata  Discosoma sp.  "magenta"	Western Pacific  Western Pacific	orange-red spots oral di blue-green stripes on o disk faintly purple oral disk

# PCT/US99/29405

"green"		
Anemonia	Mediterranean	purple tentacle tips
sulcata		

WO 00/34526

PCT/US99/29405

#### EXAMPLE 2

#### cDNA Preparation

Total RNA was isolated from the species of interest according to the protocol of Chomczynski and Sacchi (Chomczynski P., et al., Anal. Biochem. 162 (1987), 156-159). First-strand cDNA was synthetized starting with 1-3 μg of total RNA using SMART PCR cDNA synthesis kit (CLONTECH) according to the provided protocol with the only alteration being that the "cDNA synthesis primer" provided in the kit was replaced by the primer TN3 (5'- CGCAGTCGACCG(T)<sub>13</sub>, SEQ ID No. 1) (Table 2). Amplified cDNA samples were then prepared as described in the protocol provided except the two primers used for PCR were the TS primer (5'-AAGCAGTGGTATCAACGCAGAGT, SEQ ID No. 2) (Table 2) and the TN3 primer (Table 2), both in 0.1 μM concentration. Twenty to twenty-five PCR cycles were performed to amplify a cDNA sample. The amplified cDNA was diluted 20-fold in water and 1 μl of this dilution was used in subsequent procedures.

PCT/US99/29405

#### TABLE 2

Oligos Used in cDNA Synthesis and RACE

TN3: 5

5'-CGCAGTCGACCG(T)<sub>13</sub>

(SEQ ID No. 1)

T7-TN3: 5'-GTAATACGACTCACTATAGGGCCGCAGTCGACCG(T)<sub>13</sub>

(SEQ ID No. 17)

10

TS-primer: 5'-AAGCAGTGGTATCAACGCAGAGT

(SEQ ID No. 2)

T7-TS:

15 5'-GTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT

(SEQ ID No. 18)

T7:

5'-GTAATACGACTCACTATAGGGC

(SEQ ID No. 19)

20

TS-oligo

5'-AAGCAGTGGTATCAACGCAGAGTACGCrGrGrG

(SEQ ID No. 53)

25

PCT/US99/29405

# **EXAMPLE 3**

# Oligo Design

To isolate fragments of novel fluorescent protein cDNAs, PCR using degenerate primers was performed. Degenerate primers were designed to match the sequence of the mRNAs in regions that were predicted to be the most invariant in the family of fluorescent proteins. Four such stretches were chosen (Table 3) and variants of degenerate primers were designed. All such primers were directed to the 3'-end of mRNA. All oligos were gel-purified before use. Table 2 shows the oligos used in cDNA synthesis and RACE.

PCT/US99/29405

# TABLE 3

Key Amino Acid Stretches and Corresponding Degenerate Primers Used for Isolation of Fluorescent Proteins

Stretch Position	Amino Acid	
according to	Sequence of	Degenerated Primer Name
A. victoria GFP (7)	the Key Stretch	and Sequence
· -		
20-25	GXVNGH	NGH: 5'- GA(C,T) GGC TGC
	(SEQ ID No. 3)	GT(A,T,G,C) $AA(T,C)$ $GG(A,T,G)$
		CA (SEQ ID No. 4)
31-35	GEGEG	GEGa: 5'- GTT ACA GGT GA(A,G)
	(SEQ ID No. 5)	GG(A,C) GA(A,G) GG
		(SEQ ID No. 6)
		GEGb: 5'- GTT ACA GGT GA(A,G)
		GG(T,G) GA(A,G) GG
		(SEQ ID No. 7)
	GEGNG	GNGa: 5'- GTT ACA GGT GA(A,G)
	(SEQ ID No. 8)	GG(A,C) $AA(C,T)$ $GG$
		(SEQ ID No. 9)
		GNGb: 5'- GTT ACA GGT GA(A,G)
		GG(T,G) AA(C,T) GG
		(SEQ ID No. 10)
127-131	GMNFP	NFP: 5' TTC CA(C,T) GGT
	(SEQ ID No. 11)	(G,A)TG $AA(C,T)$ $TT(C,T)$ $CC$
	GVNFP	(SEQ ID NO. 13)
	(SEQ ID No. 12)	
134-137	GPVM	PVMa: 5' CCT GCC (G,A)A(C,T)
	(SEQ ID No. 14)	GGT CC(A,T,G,C) GT(A,C) ATG
		(SEQ ID NO. 15)
		PVMb: 5' CCT GCC (G,A)A(C,T)
		GGT CC(A,T,G,C) GT(G,T) ATG
		(SEQ ID NO. 16)

10

15

WO 00/34526

PCT/US99/29405

#### EXAMPLE 4

#### Isolation of 3'-cDNA Fragments of nFPs

The modified strategy of 3'-RACE was used to isolate the target fragments (see Figure 1). The RACE strategy involved two consecutive PCR steps. The first PCR step involved a first degenerate primer (Table 4) and the T7-TN3 primer (SEQ ID No. 17) which has a 3' portion identical to the TN3 primer used for cDNA synthesis (for sequence of T7-TN3, Table 2). The reason for substituting the longer T7-TN3 primer in this PCR step was that background amplification which occurred when using the shorter TN3 primer was suppressed effectively, particularly when the T7-TN3 primer was used at a low concentration (0.1 \_M) (Frohman et al., (1998) PNAS USA, 85, 8998-9002). The second PCR step involved the TN3 primer (SEQ ID No. 1, Table 2) and a second degenerate primer (Table 4).

PCT/US99/29405

TABLE 4

Combinations of Degenerate Primers for First and Second PCR Resulting in Specific Amplification of 3'-Fragments of nFP cDNA

Species	First	Second Degenerate Primer
•	Degenerate	
	Primer	
Anemonia majano	NGH	GNGb
	(SEQ ID No. 4)	(SEQ ID No. 10)
Clavularia sp.	NGH	GEGa
	(SEQ ID No. 4)	(SEQ ID No. 6)
Zoanthus sp.	NGH	GEGa
	(SEQ ID No. 4)	(SEQ ID No. 6)
Discosoma sp. "red"	NGH	GEGa (SEQ ID No. 6),
	(SEQ ID No. 4)	NFP (SEQ ID No. 13) or
		PVMb (SEQ ID No. 16)
Discosoma striata	NGH	NFP
	(SEQ ID No. 4)	(SEQ ID No. 13)
Anemonia sulcata	NGH	GEGa (SEQ ID No. 6)
	(SEQ ID No. 4)	or NFP (SEQ ID No. 13)

5

The first PCR reaction was performed as follows: 1 µl of 20-fold dilution of the amplified cDNA sample was added into the reaction mixture containing 1X Advantage KlenTaq Polymerase Mix with provided buffer (CLONTECH), 200 µM dNTPs, 0.3 µM of first degenerate

15

20

WO 00/34526 PCT/US99/29405

primer (Table 4) and 0.1 µM of T7-TN3 (SEQ ID No. 17) primer in a total volume of 20 µl. The cycling profile was (Hybaid OmniGene Thermocycler, tube control mode): 1 cycle for 95°C, 10 sec.; 55°C, 1 min.; 72°C, 40 sec; 24 cycles for 95°C, 10 sec.; 62°C, 30 sec.; 72°C, 40 The reaction was then diluted 20-fold in water and 1 µl of this dilution was added to a second PCR reaction, which contained 1X Advantage KlenTaq Polymerase Mix with the buffer provided by the manufacturer (CLONTECH), 200  $\mu M$  dNTPs, 0.3  $\mu M$  of the second degenerate primer (Table 4) and 0.1 µM of TN3 primer. The cycling profile was (Hybaid OmniGene Thermocycler, tube control mode): 1 cycle for 95°C, 10 sec.; 55°C (for GEG/GNG or PVM) or 52°C (for NFP), 1 min.; 72°C, 40 sec; 13 cycles for 95°C, 10sec.; 62°C (for GEG/GNG or PVM) or 58°C (for NFP), 30 sec.; 72°C, 40 sec. The product of PCR was cloned into PCR-Script vector (Stratagene) according the manufacturer's protocol.

Different combinations of degenerate primers were tried in the first and second PCR reactions on the DNA from each species until a combination of primers was found that resulted in specific amplification--meaning that a pronounced band of expected size (about 650-800 bp for NGH and GEG/GNG and 350-500 bp for NFP and PVM--sometimes accompanied by a few minor bands) was detected on agarose gel after two PCR reactions. The primer combinations of choice for different species of the Class Anthozoa are listed in Table 4. Some other primer combinations also resulted in amplification of fragments of correct size, but the sequence of these fragments showed no homology to the other fluorescent proteins identified or to Aequorea victoria GFP.

15

20

25

WO 00/34526

PCT/US99/29405

#### EXAMPLE 5

#### Obtaining Full-Length cDNA Copies

Upon sequencing obtained 3'-fragments the novel fluorescent protein cDNAs, two nested 5'-directed primers were synthesized for cDNA (Table 5), and the 5' ends of the cDNAs were then amplified using two consecutive PCRs. In the next PCR reaction, the nevel approach of "step-out PCR" was used to suppress background amplification. The step-out reaction mixture contained 1x Advantage KlenTaq Polymerase Mix using buffer provided by the manufacturer (CLONTECH), 200 µM dNTPs, 0.2 µM of the first gene-specific primer (see Table 5), 0.02 µM of the T7-TS primer (SEQ ID No. 18), 0.1 µM of T7 primer (SEQ ID No. 19) and 1 µl of the 20-fold dilution of the amplified cDNA sample in a total volume of 20 µl. The cycling profile was (Hybaid OmniGene Thermocycler, tube control mode): 23-27 cycles for 95°C, 10 sec.; 60°C, 30 sec.; 72°C, 40 sec. The product of amplification was diluted 50-fold in water and one µl of this dilution was added to the second (nested) PCR. The reaction contained 1X Advantage KlenTaq Polymerase Mix with provided buffer (CLONTECH), 200 μM dNTPs, 0.2 μM of the second gene-specific primer and 0.1 μM of TS primer (SEQ ID No. 2) in a total volume of 20 µl. The cycling profile was (Hybaid OmniGene Thermocycler, tube control mode): 12 cycles for 95°C, 10 sec.; 60°C, 30 sec.; 72°C, 40 sec. The product of amplification was then cloned into pAtlas vector (CLONTECH) according to the manufacturer's protocol.

# PCT/US99/29405

TABLE 5

# Gene-Specific Primers Used for 5'-RACE

Species	First Primer	Second (Nested) Primer
•		
Anemonia	5'-GAAATAGTCAGGCATACTGGT	5'-GTCAGGCATAC
majano	(SEQ ID No. 20)	TGGTAGGAT
		(SEQ ID No. 21)
Clavularia	5'-CTTGAAATAGTCTGCTATATC	5'-TCTGCTATATC
sp.	(SEQ ID No. 22)	GTCTGGGT
		(SEQ ID No. 23)
Zoanthus	5'-	5'-GTCTACTATGTCTT
sp.	GTTCTTGAAATAGTCTACTATGT	GAGGAT
	(SEQ ID No. 24)	(SEQ ID No. 25)
Discosoma	5'-CAAGCAAATGGCAAAGGTC	5'-CGGTATTGTGGCC
sp. "red"	(SEQ ID No. 26)	TTCGTA
		(SEQ ID No. 27)
Discosoma	5'-TTGTCTTCTTCTGCACAAC	5'-CTGCACAACGG
striata	(SEQ ID No. 28)	GTCCAT
		(SEQ ID No. 29)
Anemonia	5'-CCTCTATCTTCATTTCCTGC	5'-TATCTTCATTTCCT
sulcata	(SEQ ID No. 30)	GCGTAC
		(SEQ ID No. 31)
Discosoma	5'-TTCAGCACCCCATCACGAG	5'-ACGCTCAGAGCTG
sp.	(SEQ ID No. 32)	GGTTCC
"magenta"		(SEQ ID No. 33)
Discosoma	5'-CCTCAGCAATCCATCACGTTC	5'-ATTATCTCAGTGGA
sp. "green"	(SEQ ID No. 34)	TGGTTC
		(SEQ ID No. 35)

10

15

20

25

WO 00/34526

PCT/US99/29405

#### **EXAMPLE 6**

#### Expression of nFPs in E.coli

To prepare a DNA construct for novel fluorescent protein expression, two primers were synthesized for each cDNA: a 5'-directed "downstream" primer with the annealing site located in the 3'-UTR of the cDNA and a 3'-directed "upstream" primer corresponding to the site of translation start site (not including the first ATG codon) (Table Both primers had 5'-heels coding for a site for a restriction endonuclease; in addition, the upstream primer was designed so as to allow the cloning of the PCR product into the pQE30 vector (Oiagen) in such a way that resulted in the fusion of reading frames of the vectorencoded 6xHis-tag and nFP. The PCR was performed as follows: 1 µl of the 20-fold dilution of the amplified cDNA sample was added to a mixture containing 1x Advantage KlenTaq Polymerase Mix with buffer provided by the manufacturer (CLONTECH), 200 µM dNTPs, 0.2 µM of upstream primer and 0.2 µM of downstream primer, in a final total volume of 20  $\mu$ l. The cycling profile was (Hybaid OmniGene Thermocycler, tube control mode): 23-27 cycles for 95°C, 10 sec.; 60°C, 30 sec.; 72°C, 40 sec. The product of this amplification step was purified by phenol-chlorophorm extraction and ethanol precipitation and then cloned into pQE30 vector using restriction endonucleases corresponding to the primers' sequence according to standard protocols.

All plasmids were amplified in XL-1 blue *E. coli* and purified by plasmid DNA miniprep kits (CLONTECH). The recombinant clones were selected by colony color, and grown in 3 ml of LB medium (supplemented with 100 µg/ml of ampicillin) at 37°C overnight. 100 µl

WO 00/34526 PCT/US99/29405

of the overnight culture was transferred into 200 ml of fresh IB medium containing 100  $\mu$ g/ml of ampicillin and grown at 37°C, 200 rpm up to OD<sub>600</sub> 0.6-0.7. 1 mM IPTG was then added to the culture and incubation was allowed to proceed at 37°C for another 16 hours. The cells were harvested and recombinant protein, which incorporated 6x His tags on the N-terminus, was purified using TALON<sup>TM</sup> metal-affinity resin according to the manufacturer's protocol (CLONTECH).

PCT/US99/29405

TABLE\_6

Primers Used to Obtain Full Coding Region of nFPs for Cloning into Expression Construct

Species	Upstream Primer	Downstream Primer
Anemonia majano	5' -acatggatccgctctttcaaaca agtttatc (SEQ ID No. 36) BamHI	5'-tagtactcgagcttattcgta tttcagtgaaatc (SEQ ID No. 37) XhoI
Clavularia sp.	L: 5'-acatggatccaacattttttga gaaacg (SEQ ID No. 38) BamHI S: 5'-acatggatccaaagctctaacc accatg (SEQ ID No. 39) BamHI	5'-tagtactcgagcaacacaa accetcagacaa (SEQ ID No. 40) XhoI
Zoanthus sp.	5'- acatggatccgctcagtcaaag cacggt (SEQ ID No. 41) BamHI	5'-tagtactcgaggttggaactacat tcttatca (SEQ ID No. 42) XhoI
Discosoma sp. "red"	5'- acatggatccaggtcttccaagaat gttatc (SEQ ID No. 43) BamHI	5'-tagtactcgaggagccaagttc agcctta (SEQ ID No. 44) XhoI
Discosoma striata	5'- acatggatccagttggtccaagagtgtg (SEQ ID No. 45) BamHI	5'-tagcgagctctatcatgcctc gtcacct (SEQ ID No. 46) SacI
Anemonia sulcata	5'- acatggatccgcttcctttttaaagaagact (SEQ ID No. 47) BamHI	5'-tagtactcgagtccttgggagc ggcttg (SEQ ID No. 48) XhoI
Discosoma sp. "magenta"	5'- acatggatccagttgttccaagaatgtgat (SEQ ID No. 49) BamHI	5'-tagtactcgaggccattacg ctaatc (SEQ ID No. 50) XhoI
Discosoma sp. "green"	5'-acatggatccagtgcacttaaagaagaaatg (SEQ ID No. 51)	5'-tagtactcgagattcggtttaat gccttg (SEQ ID No. 52)

PCT/US99/29405

#### EXAMPLE 7

Novel Fluorescent Proteins and cDNAs Encoding the Proteins

Seven cDNA full-length cDNAs encoding fluorescent proteins were obtained (SEQ ID Nos. 45-51), and seven novel fluorescent proteins were produced (SEQ ID Nos. 53-59). The spectral properties of the isolated novel fluorescent proteins are shown in Table 7,—and the emission and excitation spectra for the novel proteins are shown in Figures 3-11.

10

PCT/US99/29405

TABLE 7

# Spectral Properties of the Isolated NFPs.

Species	NFP	Abs.	Emission	Maximum	Relative	Relative
	Name	Max.	Maximum	Extinction	Quantum	Brightness
		n m	n m	Coeff.	Yield*	**
Anemonia majano	amFP486	458	486	40,000	0.3	0.43
Clavularia sp.	cFP484	456	484	35,300	0.6	0.77
Zoanthus sp.	zFP506	496	506	35,600	0.79	1.02
Zoanthus sp.	zFP538	528	538	20,200	0.52	0.38
Discosoma sp. "red"	drFP583	558	583	22,500	0.29	0.24
Discosoma striata	dsFP483	443	483	23,900	0.57	0.50
Anemonia sulcata	asFP600	572	596	56,200	<0.001	-
Discosoma sp "green"	dgFP512	502	512	20,360	0.3	0.21
Discosoma sp. "magenta"	dmFP592	573	593	21,800	0.11	0.09

<sup>5 \*</sup>relative quantum yield was determined as compared to the quantum yield of A. victoria GFP.

<sup>\*\*</sup>relative brightness is extinction coefficient multiplied by quantum yield divided by the same value for A. victoria GFP.

PCT/US99/29405

WO 00/34526

Multiple alignment of fluorescent proteins is shown in Figure 2A. The numbering is based on Aequorea victoria green fluorescent protein (GFP, SEQ ID No. 54). The amino acid sequences of the novel fluorescent proteins are labeled as SEQ ID Nos. 55-63. Two proteins from Zoanthus and four from Discosoma are compared between each other: residues identical to the corresponding ones in the first protein of the series are represented by dashes. Introduced gaps are represented by dots. In the sequence of A. victoria GFP, the stretches forming  $\beta$ -sheets are underlined; the residues whose side chains form the interior of the  $\beta$ -can are shaded. Figure 2B shows the N-terminal part of cFP484, which has no homology with the other proteins. The putative signal peptide is underlined.

The following references were cited herein.

- 1. Ormo et al., (1996) Science 273: 1392-1395.
- 15 2. Yang, F., et al., (1996) Nature Biotech 14: 1246-1251.
  - 3. Cormack, et al., (1996) Gene 173, 33-38.
  - 4. Haas, et al., (1996) Current Biology 6, 315-324.
  - 5. Yang, et al., (1996) Nucleic Acids Research 24, 4592-4593.
  - 6. Ghoda, et al.. (1990) J. Biol. Chem. 265: 11823-11826.
- 20 7. Prasher D.C. et al. (1992) Gene 111:229-33.
  - 8. Kain et al. (1995) Biotechniques 19(4):650-55.
  - 9. Chomczynski P., et al., (1987) Anal. Biochem. 162, 156-159.
  - 10. Frohman et al., (1998) PNAS USA, 85, 8998-9002.

Any patents or publications mentioned in this specification 25 are indicative of the levels of those skilled in the art to which the and invention pertains. These patents publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated bе incorporated by reference.

WO 00/34526 PCT/US99/29405

One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

PCT/US99/29405

#### WHAT IS CLAIMED IS:

1. A method of identifying a DNA sequence encoding a fluorescent protein, comprising the step of:

screening for an existence of a nucleic acid sequence in a sample, wherein said nucleic acid sequence encodes a peptide having a sequence selected from the group consisting of SEQ ID Nos. 3, 5, 8, 11, 12 and 14, and wherein the existence of said nucleic acid sequence identifies the DNA sequence encoding the fluorescent protein.

10

15

25

5

2. A method of identifying a DNA sequence encoding a fluorescent protein, comprising the step of:

screening for an existence of a nucleic acid sequence in a sample, wherein said nucleic acid sequence hybridizes to a primer selected from the group consisting of SEQ ID Nos. 4, 6, 7, 9, 10, 13, 15 and 16, and wherein the existence of said nucleic acid sequence identifies the DNA sequence encoding the fluorescent protein.


- 3. A method of analyzing a fluorescent protein in a cell, 20 comprising the steps of:
  - a) expressing a nucleic acid sequence encoding a fluorescent protein in said cell, wherein said protein having an amino acid sequence selected from the group consisting of SEQ ID Nos. 55-63; and
    - b) measuring a fluorescence signal from said protein.
  - 4. The method of claim 3, further comprising the step of:
    sorting said cell according to said signal.

WO 00/34526

PCT/US99/29405

- 5. The method of claim 4, wherein said step of sorting comprises sorting said cell by fluorescence activated cell sorting.
- 5 6. The method of claim 3, wherein said nucleic acid sequence comprises a gene of interest encoding a protein of interest fused to said fluorescent protein, wherein said protein of interest is distinct from said fluorescent protein.
- 7. The method of claim 6, wherein the fluorescence signal indicates a presence of said gene of interest in said cell.
  - 8. The method of claim 7, wherein said cell further comprises a protein of interest fused to said fluorescent protein.
  - 9. The method of claim 8, further comprising the step of:
- identifying an intracellular location of said fluorescent protein, thereby identifying an intracellular location of said protein of 20 interest.
  - 10. An isolated and purified fluorescent protein selected from the group consisting of amFP486, cFP484, zFP506, zFP538, dsFP483, drFP583, asFP600, dgFP512 and dmFP592.

PCT/US99/29405



# PCT/US99/29405


10 20 30 40 50	
MSKGEELFTG. VVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTT. GKLPVP W CEP	SEQ ID#
MAUSKIIGLIK, EMTMKYRMECCURCUVERTMONON	. 54
· · · · · · · · · · · · · · · · · · ·	
MONONOVIAE.EMLIDIAHLEGT FNGUVEET VCVCVCVCVCVC	
M-ALY-K-N-TMVVLP-K-R-DYQ-SQELT-VSY dgFP4	83 59
-RSNSY dgFP5 M-CNF-RFKVRMVEE-E-E-R-YHK-KA- drFP5	12 62
· · · · · · · · · · · · · · · · · · ·	The state of the s
MALSNKFIGD.DMKMTYHMDGCVNGHYFTVKGEGNGKPYEGTQEMKIEVIEGGPLPFAF asFP6 KKALTTMGVIKPDMKIKLKMEGNVNGHAFVIEGEGEGERPYDGTUTT	00 61
CKALTTMGVIKPDMKIKLKMEGNVNGHAFVIEGEGEGKPYDGTHTLNLEVKMAEGAPLPFSY CFP48	86 55
60 70	4 . 56
PTLVTTFSYGVQCFSRYPDHMKQHDFFKSAM:PEGYVQERTIFFKDDGNYKTRAEVKFEGD	GFP
DILSAAFNYGNRVFTEYPQDIVDYFKNSCPAGYTWDRSFLFEDGAVCICNADITVSVEEN	zFP506
· · · · · · · · · · · · · · · · · · ·	zFP538
"IDCFUEUIGNARVHHUINID NOIVIAN	
DTTMRNY-EIF-QTCSGPNGS-Q-T-TYV-TA-SNVV-D.	dsFP483 dgFP512
DSVTA-SNVV-D  DSS-VY-K-AKFKV-NVVTV-Q-SQDG	drFP583
**	dmFP592
"THO LOCATION IF IN TACKET DE PARTY	•
DILSTVFKYGNRCFTAYPTSMPDYFKQAFPEGFTWERTTTYEDGGFLTAHQDTSLDGD DILSNAFQYGNRALTKYPDDIADYFKQSFPEGYSUBURGVATASWEISLKGN	asFP600 amFP486
DILSNAFQYGNRALTKYPDDIADYFKQSFPEGYSWERTMTFEDKGIVKVKSDISMEED	cFP484
120 130 140 150	
150 160 175	
TLVNRIELKGI DFKEDGNILGHKLEYNYNSHNVYIMADKOKNGIKVNFKI DHNI ENGRUOD	
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQL CMYHESKFYGVNFPADGPVM KKMTDNWEDGGRVAA	GFP
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQL CMYHESKFYGVNFPADGPVM KKMTDNWEDGGRVAA	GFP zFP506
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNYYIMADKQKNGIKVNFKIRHNIEDGSVQL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLKDGGRLR  -I-K-I-N-MY-  CFNYDIKFTGLNFPPNGPVV. OKKTTCME POTTER LANG.	_
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLLKDGGRLR  -I-K-I-N-MY-  CFNYDIKFTGLNFPPNGPVV.QKKTTGWEPSTERLYPRDGVLIGDIHHALTVEGGGHYV	zFP506
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNYYIMADKQKNGIKVNFKIRHNIEDGSVQL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLLKDGGRLR  -I-K-I-N-M	zFP506 zFP538
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNYYIMADKQKNGIKVNFKIRHNIEDGSVQL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLLKDGGRLR  -I-K-I-N-M	zFP506 zFP538 dsFP483
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNYYIMADKQKNGIKVNFKIRHNIEDGSVQL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLLKDGGRLR  -I-K-I-N-M	zFP506 zFP538 dsFP483 dgFP512
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNYYIMADKQKNGIKVNFKIRHNIEDGSVOL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLLKDGGRLR  -I-K-I-N-M	zFP506 zFP538 dsFP483 dgFP512 drFP583
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNYYIMADKQKNGIKVNFKIRHNIEDGSVOL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLLKDGGRLR  -I-K-I-N-M	zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592 asFP600 amFP486
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNYYIMADKQKNGIKVNFKIRHNIEDGSVOL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLIKDGGRLR -I-K-I-N-M	zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592 asFP600
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLLKDGGRLR -I-K-I-N-M	zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592 asFP600 amFP486
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVOL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLIKDGGRLR  -I-K-I-N-M	zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592 asFP600 amFP486 cFP484
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNYYIMADKQKNGIKVNFKIRHNIEDGSVOL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLIKDGGRLR -I-K-I-N-M	zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592 asFP600 amFP486 cFP484
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLLKDGGRLR -IK-I-N-M	zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592 asFP600 amFP486 cFP484
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLLKDGGRLR -IK-I-N-M	zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592 asFP600 amFP486 CFP484
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLLKDGGPLR -I-K-I-N-M	zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592 asFP600 amFP486 CFP484 GFP zFP506 zFP538 dsFP483
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLLKDGGRLR -IK-I-N-M	zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592 asFP600 amFP486 CFP484 GFP zFP506 zFP538 dsFP483 dgFP512
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVOL  CMYHESKFYGVNFPADGPVM.KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLIKDGGRLR -I-K-I-N-M	zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592 asFP600 amFP486 CFP484 GFP zFP506 zFP538 dsFP483 dgFP512 drFP583
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVOL  CMYHESKFYGVNFPADGPVM.KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLLKDGGRLR -I-K-I-N-M	zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592 asEP600 amFP486 cFP484 GFP zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNYIMADKQKNGIKVNFKIRHNIEDGSVQL  CMYHESKFYGVNFPADGPVM. KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLIKDGGRLR -IK-I-N-M	zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592 asFP600 amFP486 cFP484 GFP zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592 asFP600
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVOL  CMYHESKFYGVNFPADGPVM.KKMTDNWEPSCEKIIPVPKQGILKGDVSMYLLIKDGGRLR -I-K-I-N-M	zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592 asEP600 amFP486 cFP484 GFP zFP506 zFP538 dsFP483 dgFP512 drFP583 dmFP592

# FIG. 2A


MKCKFVFCLSFLVLAITNANIFLRNEADLEEKTLRIP

FIG. 2B 2/11 SUBSTITUTE SHEET (RULE 26)


PCT/US99/29405




3/11
SUBSTITUTE SHEET (RULE 26)




4/11
SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)



8/11

SUBSTITUTE SHEET (RULE 26)







Fig. 10

10/11
SUBSTITUTE SHEET (RULE 26)



E E

11/11
SUBSTITUTE SHEET (RULE 26)

	WO 00/34526	PCT/US99/29405
		SEQUENCE LISTING
	<110>	Lukyanov, Sergey A.
		Labas, Yulii A.
	-	Matz, Mikhail V.
5		Fradkov, Arcady F.
	<120>	Fluorescent proteins from non-bioluminescent
		species of Class Anthozoa, genes encoding such
		proteins and uses thereof
•	<130>	·
10	<141>	·
	<150>	•
	<151>	
	<160>	63
15	<210>	1
	<211>	25
	<212>	DNA
	<213>	artificial sequence
	<220>	
20	<221>	primer_bind
	<223>	primer TN3 used in cDNA synthesis and RACE
	<400>	1
	cgcagtcgac	cgttttttt ttttt 25
25	<210>	2
	<211>	23
	<212>	DNA
	<213>	artificial sequence
	<220>	
30	<221>	primer_bind
	<223>	primer TS used in cDNA synthesis and RACE
	<400>	2
	aagcagtggt	atcaacgcag agt 23
35	<210>	3
	<211>	
	<212>	PRT

	WO 00/34526		PCT/US99/29405
	<213>	Aequorea victoria	
	<220>		•
	<222>	21	- · ·
	<223>	amino acid sequence of a key stretch	n on which
5	•	primer NGH is based; Xaa at position	n 21
		represents unknown	
	<400>	3	•
	Gly Xaa Val As	n Gly His	
′	_	5	
- 10		·	
	<210>	4	•
	<211>	20	
	<212>	DNA	
	<213>	artificial sequence	
15	<220>		
	<221>	primer_bind	٠.
	<222>	12	
	<223>	primer NGH used for isolation of flu	ıorescent
		protein; n at position 12 represents	s any of the
20		four bases	
	, <400>	4	
	gayggctgcg tna	aayggdca 2	10
			٠, ٠
	<210>	5	
25	<211>	5	
	<212>	PRT	
	<213>	Aequorea victoria	
	<220>		
	<222>	3135	•.
30	<223>	amino acid sequence of a key stretch	n on which
		primers GEGa and GEGb are based	
	<400>	5	
	Gly Glu Gly Gl	lu Gly	
	•	5	
35			
	<210>	6 .	٠.
	<211>	20	

	WO 00/34526	PCT/US99/29405
	<212>	DNA
	<213>	artificial sequence
	<220>	
	<221>	primer_bind
5	<223>	primer GEGa used for isolation of fluorescent
		protein
•	<400>	6
	gttacaggtg ar	ggmgargg 20
10	<210>	7
	<211>	20
	<212>	DNA
	<213>	artificial sequence
	<220>	
15	<221>	primer_bind
	<223>	primer GEGb used for isolation of fluorescent
		protein
	<400>	. 7
	gttacaggtg ar	ggkgargg 20
20		
	<210>	8
	<211>	5
	<212>	PRT
	<213>	Aequorea victoria
25	<220>	
	<222>	3135
	<223>	amino acid sequence of a key stretch on which
		primers GNGa and GNGb are based
	<400>	8
30	Gly Glu Gly A	sn Gly
		5
	<210>	9
	<211>	20
35	<212>	DNA
	<213>	artificial sequence
	<220>	·

	WO 00/34526	PCT/US99/29405
	<221>	primer_bind
	<223>	primer GNGa used for isolation of fluorescent
		protein
	<400>	9
5	gttacaggtg	arggmaaygg 20
Ū	500000	
	<210>	10
	<211>	20
	<212>	DNA
·· 10	<213>	artificial sequence
	<220>	
	<221>	primer_bind
	<223>	primer GNGb used for isolation of fluorescent
		protein
15	<400>	10
	gttacaggtg	arggkaaygg 20
	<210>	11
	<211>	· 5
20	<212>	PRT
	<213>	Aequorea victoria
	<220>	107 121
	<222>	127131
25	<223>	amino acid sequence of a key stretch on which
25	<400>	primer NFP is based
		11
	Gly Met Asr	
		5
30	<210>	12
	<211>	5
	<212>	PRT
	<213>	Aequorea victoria
	<220>	
35	<222>	127131
	<223>	amino acid sequence of a key stretch on which
		primer NFP is based

	WO 00/34526	PCT/US99/29405
	<400>	12
	Gly Val Asn Phe	Pro
		5
	•	
5	<210>	13
-	<211>	20
	<212>	DNA
	<213>	artificial sequence
•	<220>	•
10	<221>	primer_bind
	<223>	primer NFP used for isolation of fluorescent
		protein
	<400>	13
	ttccayggtr tgaa	lyttycc 20
15	·	
	<210>	14
	<211>	4
	<212>	PRT
	<213>	Aequorea victoria
20	<220>	404 405
	<222>	134137
	<223>	amino acid sequence of a key stretch on which primers PVMa and PVMb are based
	<400>	14
		•
25	Gly Pro Val Met	<u>.</u>
	<210>	15
••	<211>	21
30	<212>	DNA
	<213>	artificial sequence
	<220> <221>	primer_bind
	<221>	15
35	<223>	primer PVMa used for isolation of fluorescent
20	- 2 2 2 -	protein; n at position 15 represents any of the

	WO 00/34526	PCT/US99/29405	
		four bases	
	<400>	15	
	cctgccrayg	gtccngtmat g 21	
5	<210>	16	
	<211>	21	
	<212>	DNA	
	<213>	artificial sequence	
	<220>		
10	<221>	primer_bind	
	<222>	15	
	<223>	primer PVMb used for isolation of fluorescent	
		protein; n at position 15 represents any of the	
		four bases	
15	<400>	16	
	cctgccrayg	gtccngtkat g 21	
	<210>	. 17	
	<211>	47	
20	<212>	DNA	
	<213>	artificial sequence	
	<220>		
	<221>	primer_bind	
	<223>	primer T7-TN3 used in cDNA synthesis and RACE	
25	<400>	17	
	gtaatacgac	tcactatagg gccgcagtcg accgtttttt ttttttt	47
	<210>	18	
	<211>	45	
30	<212>	DNA	•
	<213>	artificial sequence	
	<220>		
	<221>	primer_bind	
	<223>	primer T7-TS used in cDNA synthesis and RACE	
35	<400>	18	
	gtaatacgac	tcactatagg gcaagcagtg gtatcaacgc agagt	45

	WO 00/34526	PCT/US9	9/29405
	<210>	19	
	<211>	22	
	<212>	DNA	•
5	<213>	artificial sequence	
	. <220>		
	<221>	primer_bind	
	<223>	primer T7 used in cDNA synthesis and RACE	
	<400>	19	
10	~gtaatacgac	tcactatagg gc 22	٠,
	-	· · · · · · · · · · · · · · · · · · ·	
•	<210>	20	
	<211>	21	•
	<212>	DNA	
15	<213>	artificial sequence	
	<220>		٠,
	<221>	primer_bind	
	<223>	gene-specific primer used for 5'-RACE for	
		Anemonia majano	
20	<400>	20	
	gaaatagtca	ggcatactgg t 21	
			٠.
	<210>	21	
	<211>	20	
25	<212>	DNA	
	<213>	artificial sequence	
	<220>		
	<221>	primer_bind	
	<223>	gene-specific primer used for 5'-RACE for	·•
30		Anemonia majano	
	<400>	21	
	gtcaggcata	ctggtaggat 20	
	<210>	22	
35	<211>		٠.

	WO 00/34526	PCT/US99	/29405
	<212>	DNA	
	<213>		
	<220>	201110101	
	<221>	primer_bind	
5	<223>	gene-specific primer used for 5'-RACE for	٠.
,	1225	Clavularia sp.	•
	<400>	22	
	cttgaaatag	tctgctatat c 21	
	<u>.</u>		
10	<210>	23	
	<211>		٠.
	<212>	·	
	<213>		
	<220>	-	
15	<221>	primer_bind .	
	<223>	gene-specific primer used for 5'-RACE for	
		Clavularia sp.	
	<400>	23	·• ·
	tctgctatat	cqtctqqqt 19	
••			
20	.010	0.4	
	<210>	$\cdot$	
	<211>		
	<212>		٠.
0.5	<213>	artificial sequence	
25	<220>		
	<221>	<del>-</del>	
	<223>	gene-specific primer used for 5'-RACE for Zoanthus sp.	
	-100>		
	<400>	·	
30	gttcttgaaa	tagtctacta tgt 23	٠.
	<210>	25	
	<211>	20	
	<212>	DNA	
35	<213>	artificial sequence	

	WO 00/34526	PCT/US99/29 <sub>4</sub>	105
	<220>		
	<221>	primer_bind	
	<223>	gene-specific primer used for 5'-RACE for	
		Zoanthus sp.	
5	<400>	25	
		•	
	gtctactatg	tcttgaggat 20	
	<210>	26	
	<211>	19	
10	<212>	DNA .	
	<213>	artificial sequence	
	<220>		
	<221>	primer_bind	
	<223>	gene-specific primer used for 5'-RACE for	
15		Discosoma sp. "red"	
	<400>	26	
	caagcaaatg	gcaaaggtc 19	
	<210>	27	
20	<211>	19	
	<212>	DNA	
	<213>	artificial sequence	
	<220>	<u>-</u>	
	<221>	primer_bind	
25	<223>	gene-specific primer used for 5'-RACE for	
		Discosoma sp. "red"	
	<400>	27	
	. aaat attata	gccttcgta 19	
	cggtattgtg	geettegta	
		*	
30	<210>	28	
	<211>	19	
	<212>		
	<213>	artificial sequence	
	<220>		
35	<221>		
	<223>	gene-specific primer used for 5'-RACE for	

	WO 00/34526	·	PCT/US99/29405
	٠.	Discosoma striata	
	<400>	28	•
	ttgtcttctt	ctgcacaac	19
5	<210>	29	• ;
	<211>	17	
	<212>	DNA	
	<213>	artificial sequence	٠.
	<220>	·	
10	~<221>	primer_bind	
	<223>	gene-specific primer use	ed for 5'-RACE for
		Discosoma striata	·
	<400>	29	
	ctgcacaacg	ggtccat	17
15			<del>-</del> /, .
	<210>	30	
	<211>	20	
	<212>	DNA	
	<213>	artificial sequence	
20	<220>	-	
	<221>	primer_bind	
	<223>	gene-specific primer use	ed for 5'-RACE for
		Anemonia sulcata	
	<400>	30	
25	cctctatctt	catttcctgc	20
	<210>	31	·.
	<211>	20	
	<212>	DNA	
30	<213>	artificial sequence	
	<220>		
	<221>	primer_bind	
	<223>	gene-specific primer use	ed for 5'-RACE for
		Anemonia sulcata	·.
35	<400>	31	
	tatcttcatt	tcctgcgtac	20

	WO 00/34526	PCT/US	9/29405
	<210>	32	
	<211>	19	••
	<212>	DNA	
5	<213>	artificial sequence	
	<220>		
	<221>	primer_bind	
	<223>	gene-specific primer used for 5'-RACE for	
		Discosoma sp. "magenta"	
10	<400>	32	
	ttcagcaccc	catcacgag 19	
	000		
	<210>	33	
	<211>		
15	<212>	DNA	
	<213>	artificial sequence	4.
	<220>	-	
	<221>	primer_bind	
	<223>	gene-specific primer used for 5'-RACE for	
20		Discosoma sp. "magenta"	
	<400>	33	
	acgctcagag	ctgggttcc 19	
	aogoooagag	19	••
	<210>	34	
25	<211>	22	
	<212>	DNA .	
	<213>	artificial sequence	
	<220>		
	<221>	primer_bind	٠.
30	<223>	gene-specific primer used for 5'-RACE for	
	•	Discosoma sp. "green"	
	<400>	34	
	ccctcagcaa	tccatcacgt tc 22	
	_		
35	<210>	35	
	<211>	20	•
	<212>	DNA	

SEQ 11/28

	WO 00/34526	PCT/US99/29405
	<213>	artificial sequence
	<220>	arcificiar sequence
	<221>	primer_bind
	<223>	gene-specific primer used for 5'-RACE for
5		Discosoma sp. "green"
	<400>	35
	attatctcag	tggatggttc 20
	<210>	36
- 10	<211>	31
	<212>	DNA
	<213>	artificial sequence
	<220>	
	<221>	primer_bind
15	<223>	upstream primer used to obtain full coding region
		of nFPs from Anemonia majano
	<400>	36
	acatggatcc	gctctttcaa acaagtttat c 31
20	<210>	
	<211>	34
	<212>	
	<213>	artificial sequence
0.5	<220>	and many Andrea A
25	<221>	-
	<223>	downstream primer used to obtain full coding region of nFPs from Anemonia majano
	<400>	
	tagtactcga	gcttattcgt atttcagtga aatc 34
30	24.2	
	<210>	
	<211>	
	<212> <213>	
35	<213> <220>	-
33	<221>	
	<223>	- ,
	/E27/	appercum primer about to obtain rain coarny region

	WO 00/34526		PCT/US9	9/29405
		of nPDs from Clarniania	. an	
	<400>	of nFPs from <i>Clavularia</i> 38	ı sp.	
	<b>\400</b> >	36		
	acatggatcc	aacattttt tgagaaacg	29	
			•	
5	<210>			
	<211>			••
	<212>		•	
	<213>	•		
	<220>			
10	<221>			
	<223>	upstream primer used to	obtain full coding	region
		of nFPs from Clavularia	ı sp.	•
	<400>	39		•
	acatggatcc	aaagctctaa ccaccatg	28	
15			•	
	<210>	40	•	
	<211>	31		
	<212>	DNA		
	<213>	artificial sequence		٠.
20	<220>			
	<221>	primer_bind		
	<223>	downstream primer used	to obtain full codir	ng
		region of nFPs from Cla	vularia sp.	
	<400>	40		
25	tagtactcga	gcaacacaaa ccctcagaca a	31	·.
		g	<del></del>	
	<210>	41		
	<211>	28		
	<212>	DNA		
30	<213>	artificial sequence		
	<220>			
	<221>	primer_bind		**
	<223>	upstream primer used to	obtain full coding	region
		of nFPs from Zoanthus s	p.	
35	<400>	41	·	
	acatggatcc	gctcagtcaa agcacggt	28	

	WO 00/34526		PCT/US99/29405
	<210>	. 42	٠.
	<211>		
	<212>		
5	<213>	artificial sequence	
	<220>	-	
	<221>	primer_bind	
	<223>	downstream primer used to obtain	full coding
		region of nFPs from Zoanthus sp.	
10	<400>	42	
	tagtactcga	ggttggaact acattcttat ca	32
	<210>	43	
	<211>		
15	<212>		•
	<213>		•
	<220>	•	
	<221>	primer_bind	
,	<223>		all coding region
20		of nFPs from Discosoma sp. "red"	
	<400>	43	
	acatggatcc	aggtetteca agaatgttat c	31
	<210>	44	
25	<211>	29	
	<212>	DNA	
	<213>	artificial sequence	
	<220>		٠.
	<221>	primer_bind	
30	<223>		
		region of nFPs from Discosoma sp.	"red"
	<400>	44	
	tagtactcga	ggagccaagt tcagcctta	29
35	<210>	45	``
	<211>	28	
	<212>		

	WO 00/34526	PCT/US99/29405
	<213>	artificial sequence
	<220>	
	<221>	
	<223>	
5		of nFPs from Discosoma striata
	<400>	45
	acatggatcc	agttggtcca agagtgtg 28
	<210>	46
10	<211>	· · · · · · · · · · · · · · · · · · ·
	<212>	
	<213>	artificial sequence
	<220>	· ·
	<221>	primer_bind
15	<223>	downstream primer used to obtain full coding
		region of nFPs from Discosoma striata
	<400>	46
	tagcgagctc	tatcatgcct cgtcacct 28
20	<210>	47
	<211>	31
	<212>	DNA
	<213>	artificial sequence
	<220>	
25	<221>	primer_bind
	<223>	upstream primer used to obtain full coding region
		of nFPs from Anemonia sulcata
	<400>	47
	acatggatcc	gcttcctttt taaagaagac t 31
30		
	<210>	48
	<211>	28
	<212>	DNA
	<213>	artificial sequence
35	<220>	
	<221>	primer_bind
	<223>	downstream primer used to obtain full coding

		region of nFPs from Anemonia sulcata	
	<400>		
	h	ataattaana maraatta	
	tagtactcga	gtccttggga gcggcttg 28	•
5	<210>		
	<211>		
	<212>		
•	<213>		
	<220>	-	
10	<221>	·	
	<223>	•	na region
		of nFPs from Discosoma sp. "magenta"	99
	<400>		
15	acatggatee	agttgttcca agaatgtgat 30	
13	<210>	50	
	<211>		
			•
	<212>	•	
20	<213> <220>	-	
20	<221>		
	<223>	-	dina
	<b>\ZZ3</b> /	region of nFPs from Discosoma sp. "magen	_
	<400>	-	·.
25	tagtactcga	ggccattacg ctaatc 26	
			•
	<210>		
	<211>		
	<212>		
30	<213>	•	*•
	<220>		
	<221>		
	<223>		ng region
2.5	400	of nFPs from Discosoma sp. "green"	
35	<400>	51	
	acatggatcc	agtgcactta aagaagaaat g 31	٠,

	WO 00/34526			PCT/US99/29405
	<210>	52		
	<211>	29		
	<212>	DNA		
5	<213>	artificial	sequence	
	<220>			٠.
	<221>	<pre>primer_bind</pre>		
	<223>	downstream	primer used to obtai	n full coding
		region of n	FPs from <i>Discosoma</i> s	sp. "green"
. 10	<400>	52		
	tagtactcga	gattcggttt aatgo	cttg	29
	<210>	53		
	<211>	33		
15	<212>	DNA		
	<213>	artificial :	sequence	
	<220>		•	•
	<221>	primer_bind		
	<223>	TS-oligo us	ed in cDNA synthesis	and RACE
20	<400>	53		
	aagcagtggt	atcaacgcag agtac	gcrgr grg	33
	<210>	54		
	<211>	238		
25	<212>	PRT		. **
	<213>	Aequorea vi	ctoria	••
	<220>			
	<223>	•	sequence of GFP	
20	<400>	54	m) m) o1	
30	met ser Lys		Phe Thr Gly Val Va	
	Wal Cluston	5	10	15
	vai Giu Leu	20	Asn Gly His Lys Ph	·.
	Gly Glu Glu		. Thr Tyr Gly Lys Le	30 u Thr Leu Ive
35	ory ora ory	35	40	u nn beu bys 45
	Phe Ile Cvs		Leu Pro Val Pro Tr	
		50	55	60 file in the co
				• •

	Val	Thr	Thr	Phe	Ser 65	Tyr	Gly	Val	Gln	Cys 70	Phe	Ser	Arg	Tyr	Pro 75
	Δen	His	Met	Live	_	Hic	Δen	Phe	Phe		Ser	λla	Met	Pro	
	, , ,	1110		טעט	80	1110	nop	1110	1110	85	DCI	niu	1100	110	90
. 5	Glv	ጥህተ	Val	Gln		Ara	Thr	Tle	Phe		Lvs	Asp.	Asn	ទាំប	
J	0-1	-3-	• • • • • • • • • • • • • • • • • • • •	0	95	9	****			100	בינב	1100	1100	011	105
	Tvr	Lvs	Thr	Ara		Glu	Val	Lvs	Phe		Glv	Asp	Thr	Len	
	-1-	27.2		9	110			_1.0		115	017			200	120
	Asn	Ara	Ile	Glu		Lvs	Glv	Ile	Asp		Lvs	Glu	Asp	Glv	٠.
10		-	٠.		125					130				1	135
			Gly	His		Leu	Glu	Tyr	Asn		Asn	Ser	His	Asn	
			-		140			-		145					150
	Tyr	Ile	Met	Ala	Asp	Lys	Gln	Lys	Asn	Gly	Ile	Lys	Val	Asn	Phe
					155					160					165
15	Lys	Ile	Arg	His	Asn	Ile	Glu	Asp	Gly	Ser	Val	Gln	Leu	Ala	Asp
					170					175					180
	His	Tyr	Gln	Gln	Asn	Thr	Pro	Ile	Gly	Asp	Gly	Pro	Val	Leu	Leu
					185					190					195
	Pro	Asp	Asn	His	Tyr	Leu	Ser	Thr	Gln	Ser	Ala	Leu	Ser	Lys	Asp
20					200					205					210
	Pro	Asn	Glu	Lys	Arg	Asp	His	Met	Val	Leu	Leu	Glu	Phe	Val	Thr
					215					220					225 -
	Ala	Ala	Gly	Ile		His	Gly	Met	Asp	Glu	Leu	Tyr	Lys		
25					230					235					
23		<2	10>		55										
			11>		229										
		<2	12>		PRT										
		<2	13>		Anem	onia	maj	ano							٠,
30		<2	20>												
		<2	23>		amin	o ac	id s	eque	nce	of a	mFP4	86			
		<4	00>		55										
	Met	Ala	Leu	Ser	Asn	Lys	Phe	Ile	${\tt Gly}$	Asp	Asp	Met	Lys	Met	Thr
					5					10					15
35	Tyr	His	Met	Asp	Gly	Cys	Val	Asn	Gly	His	Tyr	Phe	Thr	Val	Lys
					20					25					30 .
	Gly	Glu	Gly	Asn	Gly	Lys	Pro	Tyr	Glu	Gly	Thr	Gln	Thr	Ser	Thr
					35					40					45

	Phe	Lys	Val	Thr	Met	Ala	Asn	Gly	Gly	Pro	Leu	Ala	Phe	Ser	Phe	
					50					55					60	
	Asp	Ile	Leu	Ser	Thr	Val	Phe	Lys	Tyr	Gly	Asn	Arg	Cys	Phe	Thr	٠.
					65	٠				70					75	
5	Ala	Tyr	Pro	Thr	Ser	Met	Pro	Asp	Tyr	Phe	Lys	Gln	Àla	Phe	Pro	
					80					85					90	
	Asp	Gly	Met	Ser	Tyr	Glu	Arg	Thr	Phe	Thr	Tyr	Glu	Asp	${\tt Gly}$	Gly	
					95					100					105	
	Val	Ala	Thr	Ala	Ser	Trp	Glu	Ile	Ser	Leu	Lys	${\tt Gly}$	Asn	Cys	Phe	
10		-	٠		110					115					120	٠.
	Glu	His	Lys	Ser	Thr	Phe	His	Gly	Val	Asn	Phe	Pro	Ala	Asp	Gly	,
					125					130					135	
	Pro	Val	Met	Ala	Lys	Lys	Thr	Thr	Gly	Trp	Asp	Pro	Ser	Phe	Glu	
					140	•				145					150	
15	Lys	Met	Thr	Val	Суѕ	Asp	Gly	Ile	Leu	Lys	Gly	Asp	Val	Thr	Ala	
·					155					. 160					165	
	Phe	Leu	Met	Leu	Gln	Gly	Gly	Gly	Asn	Tyr	Arg	Cys	Gln	Phe	His	•
					170					175					180	
	Thr	Ser	Tyr	Lys	Thr	Lys	Lys	Pro	Val	Thr	Met	Pro	Pro	Asn	His	
20					185					190					195	
	Val	Val	Glu	His	Arg	Ile	Ala	Arg	Thr		Leu	Asp	Lys	Gly		
					200					205			_		210	
	Asn	Ser	Val	Gln	Leu	Thr	Glu	His	Ala		Ala	His	Ile	Thr		٠.
	_				215					220					225	
25	Val	Val	Pro	Phe												
		<2	10>		56											
		<2	11>		266											
30		<2	12>		PRT											٠.
		<2	13>		Clav	ular	iá s	p.								
		<2	20>													
			23>		amin	o ac	id s	eque	nce	of c	FP48	4				
			00>		56											
35	Met	Lys	Cys	Lys	Phe	Val	Phe	Cys	Leu		Phe	Leu	Val	Leu		
	•				5					10					15	

Ile Thr Asn Ala Asn Ile Phe Leu Arg Asn Glu Ala Asp Phe Glu

					20					25					30
	Glu	Lys	Thr	Phe	Arg	Ile	Pro	Lys	Ala	Leu	Thr	Thr	Met	Gly	Val
					35					40					45
	Ile	Lys	Pro	Asp	Met	Lys	Ile	Lys	Leu	Lys	Met	Glu	Gly	Asn	Val
5					50					55				•	60
	Asn	Gly	His	Ala	Phe	Val	Ile	Glu	Gly		Gly	Glu	Gly	Lys	Pro
	•		_		65					70					75
	Tyr	Asp	Gly	Thr	His	Thr	Leu	Asn	Leu		Val	Lys	Glu	Gly	
10	_	-	5	D1	80	<b></b>		<b>+7</b>	<b>-</b>	85			-1	~7	90
10	Fro	jeu	Pro	Pne	Ser	ıyr	Asp	тте	ьeи		Asn	Ата	Pne	GIn	_
	C1	· ·	7~~	775	95 Lou	Why	Tarc	Пъгъ	Dro	100	y an	T10	71-	ħ an	105
	GIY	ASII	Arg	AIG	Leu 110	1111	цуъ	тут	PLO	115	Аър	TIE	Ala	Asp	120
	Phe	T <sub>V</sub> S	Gln	Ser	Phe	Pro	Glu	Glv	Tvr		Tro	Glu	Ara	ጥ ከጉ	
15	1110	בינם	02	501	125		014	0-7	-1-	130			9		135
	Thr	Phe	Glu	Asp	Lys	Gly	Ile	Val	Lys		Lys	Ser	Asp	Ile	
				-	140	-			-	145	-		-		150
	Met	Glu	Glu	Asp	Ser	Phe	Ile	Tyr	Glu	Ile	Arg	Phe	Asp	Gly	Met
					155					160					165
20	Asp	Phe	Pro	Pro	Asn	Gly	Pro	Val	Met	Gln	Lys	Lys	Thr	Leu	Lys
					170					175					180
	Trp	Glu	Pro	Ser	Thr	Glu	Ile	Met	Tyr	Val	Arg	Asp	Gly	Val	Leu
					185					190					195
	Val	Gly	Asp	Ile	Ser	His	Ser	Leu	Leu		Glu	Gly	Gly	Gly	
25					200			_		205					210
	Tyr	Arg	Суѕ	Asp	Phe	Lys	Ser	Ile	Tyr	_	Ala	Lys	Lys	Val	
	T	T	D	3	215	77 <i>2</i> m	Dha	17- 7	3	220	3	T1 -	<b>03</b>	<b>7</b> 7.	225
	гўs	Leu	Pro	Asp	Tyr	HIS	Pne	vaı	Asp		Arg	тте	GIU	TTE	
30	λen	Hic	λαn	Lare	230 Asp	Фил	Acn	Lve	บอไ	235	Lou	Ma zac	Glu	λcn	240
50	ASII	1113	nsp	בעם	245	171	Non	БУS	Val	250	Deu	131	GIU	ASII	255
	Val	Ala	Ara	Tvr	Ser	Leu	Leu	Pro	Ser		Ala				
				-	260					265					
35		د2	10>		57										
			11>		230										
			12>		PRT										

	•			•											
		<2	13>		Zoan	thus	sp.								
		<2	20>		•										
		<2	23>		amin	o ac	id s	eque	nce	of z	FP50	6			
		<4	00>	•	57										
5	Ala	Gln	Ser	Lys	His	Gly	Leu	Thr	Lys	Glu	Met	Thr	Met	Lys	Tyr
					5					10					15
	Arg	Met	Glu	Gly	Cys	Val	Asp	Gly	His	Lys	Phe	Val	Ile	Thr	Gly
					20					25					30
	Glu	Gly	Ile	Gly	Tyr	Pro	Phe	Lys	Gly	Lys	Gln	Ala	Ile	Asn	Leu
10	<sub>-</sub> .		•		35					40					45
	Суѕ	Val	Val	Glu	Gly	Gly	Pro	Leu	Pro	Phe	Ala	Glu	Asp	Ile	Leu
					50					55					60
	Ser	Ala	Ala	Phe	Asn	Tyr	Gly	Asn	Arg	Val	Phe	Thr	Glu	Tyr	Pro
					65					70					75
15	Gln	Asp	Ile	Val	Asp	Tyr	Phe	Lys	Asn	Ser	Суѕ	Pro	Ala	Gly	Tyr
					80					85					90
	Thr	Trp	Asp	Arg	Ser	Phe	Leu	Phe	Glu	Asp	Gly	Ala	Val	Суз	
					95					100					105
	Суѕ	Asn	Ala	Asp		Thr	Val	Ser	Val		Glu	Asn	Cys	Met	
20					110					115					120
	His	Glu	Ser	Lys		Tyr	Gly	Val	Asn		Pro	Ala	Asp	Gly	
					125					130					135
	Val	Met	Lys	Lys		Thr	Asp	Asn	Trp		Pro	Ser	Cys	Glu	
	_	_		_	140					145			_		150
25	Ile	Ile	Pro	Val		Lys	Gln	Glу	Ile		Lys	Gly	Asp	Val	
		_	_	_	155	_			~3	160	_	_	_		165
	Met	чуr	Leu	Leu		гла	Asp	GIY	GIĀ			Arg	Cys	Gin	
	•	ml	**- 7	<b></b>	170			<b>G</b>	**- 7	175		<b>.</b>	30-1	5	180
20	Asp	Thr	Val	туr		Ala	гуз	ser	vaı		Arg	гуs	Met	Pro	
30	m	774 -	nh -	<b>7</b> 7.	185	TT 2	<b>T</b>	T	r Mlass	190	<b>01</b>	3	3	G	195
	тр	HIS	Phe	TTE	200	HIS	гуѕ	Leu	THE		GIU	Asp	Arg	ser	
	71-	T	3 00	Cl n		m	ui a	T 011	mb w	205	w.	77~	T1.	21-	210
	MId	пλя	Asn	GIII	215	ттЪ	urs	neu	THE	220	HIS	WIG	тте	AId	225
35	Glv	Ser	<b>Δ</b> ]=	T.e.v						220					425
	GTĀ	⊃CT.	Ala	neu	230										
					230										

	•		04520	•										rci	1/0399/2
				,											
		<2	10>		58							•			
		<2:	11>		23,0										
		<2	12>		PRT										
5		<2	13>		Zoan	thus	sp.						•	7	
		<2	20>												
		<2	23>		amin	o ac	id s	eque	nce	of z	FP53	8			
		<4	<00		58										
	Met	Ala	His	Ser	Lys	His	Gly	Leu	Lys	Glu	Glu	Met	Thr	Met	Lys
10			-		5					10					15
	Tyr	His	Met	Glu	Gly	Cys	Val	Asn	Gly	His	Lys	Phe	Val	Ile	Thr
					20					25					30
	Gly	Glu	Gly	Ile	Gly	Tyr	Pro	Phe	Lys	Gly	Lys	Gln	Thr	Ile	Asn
					35					40					45
15	Leu	Cys	Val	Ile	Glu	Gly	Gly	Pro	Leu	Pro	Phe	Ser	Glu	Asp	Ile
					50					55					60
	Leu	Ser	Ala	Gly	Phe	Lys	Tyr	Gly	Asp	Arg	Ile	Phe	Thr	Glu	Tyr
					65					70					75
	Pro	Gln	Asp	Ile	Val	Asp	Tyr	Phe	Lys	Asn	Ser	Cys	Pro	Ala	Gly
20				•	80					85					90
	Tyr	Thr	Trp	Gly		Phe	Leu	Phe	Glu		Gly	Ala	Val	Cys	Ile
					95					100					105
	Cys	Asn	Val	Asp		Thr	Val	Ser	Val		Glu	Asn	Cys	Ile	
					110					115					120
25	His	Lys	Ser	Ile		Asn	Gly	Met	Asn		Pro	Ala	Asp	Gly	
			_		125		_,	_	_	130		_	_		135
	Val	Met	Lys	Lys		Thr	Thr	Asn	Trp		Ala	Ser	Cys	Glu	_
			_	7	140	_		~ 3		145	_	~1	_		150
20	TTE	Met	Pro	Val		ьуs	Gin	GIY	TTE		Lys	GIY	Asp	Val	
30	Mot		T	T	155	T	3	Q7	01	160	m	3	<b>~</b>	01	165 Ph-
	Met	туг	Leu	ьеи	ьеи 170	гЛs	Asp	GIĀ	GIY		туг	Arg	Cys	GIN	
	) an	(III)	Val	m		71-	T	C	17-1	175	C	T	Mak	Desa	180
	MSD	1111	vaı	TÄT	185	Ата	цуs	ser	val		Set	цуs	Mec	PIO	
35	Фът.	Hic	Phe	Tle		Hic	Lare	Leu	Leu	190	Gl.	7 cz	<b>አ</b> ~~	Co~	195
55	тър	1112	FIIG	TTG	200	IIIS	пуз	⊔ <del>c</del> u	пeп	205	GIU	мър	wrd	Ser	210
	λla	Tare	Asn	Gln		ጥተ	Gln	וים. ז	ጥኮኍ		Hic	λls	Tle	<b>λ</b> 1 =	
	u	د برد		<b>V</b> 111	215	Þ	J111	<b>⊥</b> ∈u	****	220	1112	та	TTC	NT.	225
										220					223

35

WO 00/34526 PCT/US99/29405

Pro Ser Ala Leu Ala 230

5 <210> 59
<211> 232
<212> PRT
<213> Discosoma striata
<220>

10 --- <223> amino acid sequence of dsFP483 <400> 59

Met Ser Cys Ser Lys Ser Val Ile Lys Glu Glu Met Leu Ile Asp
5 10 15

Leu His Leu Glu Gly Thr Phe Asn Gly His Tyr Phe Glu Ile Lys
20 25 30

Gly Lys Gly Lys Gly Gln Pro Asn Glu Gly Thr Asn Thr Val Thr
35 40 45

Leu Glu Val Thr Lys Gly Gly Pro Leu Pro Phe Gly Trp His Ile
50 55 60

Leu Cys Pro Gln Phe Gln Tyr Gly Asn Lys Ala Phe Val His His

Pro Asp Asn Ile His Asp Tyr Leu Lys Leu Ser Phe Pro Glu Gly

Tyr Thr Trp Glu Arg Ser Met His Phe Glu Asp Gly Gly Leu Cys

25 95 100 105

Cys Ile Thr Asn Asp Ile Ser Leu Thr Gly Asn Cys Phe Tyr Tyr 110 115 120

Asp Ile Lys Phe Thr Gly Leu Asn Phe Pro Pro Asn Gly Pro Val
125 130 135

30 Val Gln Lys Lys Thr Thr Gly Trp Glu Pro Ser Thr Glu Arg Leu

140 145 150
Two Pro Arg Asp Gly Val Leu Tle Gly Asp Tle His His Ala Leu

Tyr Pro Arg Asp Gly Val Leu Ile Gly Asp Ile His His Ala Leu 155 160 165

Thr Val Glu Gly Gly His Tyr Ala Cys Asp Ile Lys Thr Val 170 175 180

Tyr Arg Ala Lys Lys Ala Ala Leu Lys Met Pro Gly Tyr His Tyr

185 190 195

PCT/US99/29405

Val Asp Thr Lys Leu Val Ile Trp Asn Asp Lys Glu Phe Met 200 Lys Val Glu Glu His Glu Ile Ala Val Ala Arg His His Pro Phe 215 220 225 · Tyr Glu Pro Lys Lys Asp Lys 230 <210> 60 <211> 225 <212> 10 PRT <213> Discosoma sp. "red" <220> <223> amino acid sequence of drFP583 <400> Met Arg Ser Ser Lys Asn Val Ile Lys Glu Phe Met Arg Phe Lys 15 15 Val Arg Met Glu Gly Thr Val Asn Gly His Glu Phe Glu Ile Glu 20 25 Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly His Asn Thr Val Lys 20 35 40 45 Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile 50 55 Leu Ser Pro Gln Phe Gln Tyr Gly Ser Lys Val Tyr Val Lys His 70 65 75 Pro Ala Asp Ile Pro Asp Tyr Lys Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Val Val 95 100 105 Thr Val Thr Gln Asp Ser Ser Leu Gln Asp Gly Cys Phe Ile Tyr 30 115 120 110 Lys Val Lys Phe Ile Gly Val Asn Phe Pro Ser Asp Gly Pro Val 125 135 Met Gln Lys Lys Thr Met Gly Trp Glu Ala Ser Thr Glu Arg Leu 140 145 150 Tyr Pro Arg Asp Gly Val Leu Lys Gly Glu Ile His Lys Ala Leu 155 Lys Leu Lys Asp Gly Gly His Tyr Leu Val Glu Phe Lys Ser Ile 170 175 180 ·

	Tyr	Met	Ala	Lys	Lys 185	Pro	Val	Gln	Leu	Pro 190	Gly	Tyr	Tyr	Tyr	Val 195
	Asp	Ser	Lys	Leu	Asp	Ile	Thr	Ser	His	Asn	Glu	Asp	Tyr	Thr	Ile
					200					205					210
5	Val	Glu	Gln	Tyr	Glu	Arg	Thr	Glu	Gly	Arg	His	His	Leu	Phe	Leu
					215					220					225
			10>		61							•			
			11>		232										
10	<del></del> <sub>s</sub> .	<2.			PRT		-								
			13>		Anem	onıa	suı	cata							
			20> 23>	-	amin	0 20	: <i>a</i>	00110	ngo	of a	arne	00			
			23 <i>&gt;</i> 00>		amırı 61	o ac	ıa s	eque	lice	OI a	SrPo	00			
15	Met				Leu	Īvs	Lvs	Thr	Met	Pro	Phe	Lvs	Thr	Thr	Tle
13	1100		501		5	_, 5	2,2			10		2,0			15
	Glu	Glv	Thr	Val	Asn	Gly	His	Tyr	Phe		Cys	Thr	Gly	Lys	
		-			20	-		_		25	-		-	_	30
	Glu	Gly	Asn	Pro	Phe	Glu	Gly	Thr	Gln	Glu	Met	Lys	Ile	Glu	Val
20					35					40				•	45
	Ile	Glu	Gly	Gly	Pro	Leu	Pro	Phe	Ala	Phe	His	Ile	Leu	Ser	Thr
					50					55					60
	Ser	Cys	Met	Tyr	Gly	Ser	Lys	Thr	Phe		Lys	Tyr	Val	Ser	
					65					70					75
25	Ile	Pro	Asp	Tyr	Phe	Lys	Gln	Ser	Phe		Glu	Gly	Phe	Thr	
	~ 3	_	am1	_,	80	_	<b>~</b> 1		~1	85	21.	<b>-</b> .	<b>50</b> 3		90
	GIU	Arg	Thr	Thr	Thr	туr	GIU	Asp	GIĀ		Pne	Leu	Thr	AIA	
	Gln	Acn.	mbr.	Ser	95 Leu	λen	Glv	λen	Cve	100	Wal	ጥኒን፦	Lve	Val	105
30	GIII	дел	1111	361	110	rop	Gry	nsp	Cys	115	VUI	-7-	Буб	Val	120
50	Ile	Leu	Glv	Asn	Asn	Phe	Pro	Ala	Asp		Pro	Val	Met	Gln	
•			4		125				_	130					135
	Lys	Ala	Gly	Arg	Trp	Glu	Pro	Ala	Thr	Glu	Ile	Val	Tyr	Glu	Val
					140					145					150
35	Asp	Gly	Val	Leu	Arg	Gly	Gln	Ser	Leu	Met	Ala	Leu	Lys	Cys	Pro
					155					160					165
	Gly	Gly	Arg	His	Leu	Thr	Cys	His	Leu	His	Thr	Thr	Tyr	Arg	Ser
					170					175					180

	Lys	Lys	Pro	Ala	Ser	Ala	Leu	Lys	Met	Pro	Gly	Phe	His	Phe	Glu
					185		•			190					195
	Asp	His	Arg	Ile	Glu	Ile	Met	Glu	Glu	Val	Glu	Lys	Gly	Lys	Cys
			•		200					205					210
5	Tyr	Lys	Gln	Tyr	Glu	Ala	Ala	Val	${\tt Gly}$	Arg	Tyr	Cys	Asp	Ala	Ala
					215					220					225
	Pro	Ser	Lys	Leu	${\tt Gly}$	His	Asn								
					230										

	~ · · · ·														
10		<2	10>		62										
		<2	11>		231										
		<2	12>		PRT										
		<2	13>		Disc	osom	a sp	. "g	reen	"	•				
		<23	20>												
15	<223> amino acid sequence of dgFP512														
	<400> 62														
	Met	Ser	Ala	Leu	Lys	Glu	Glu	Met	Lys	Ile	Asn	Leu	Thr	Met	Glu
					5					10					15
	Gly	Val	Val	Asn	Gly	Leu	Pro	Phe	Lys	Ile	Arg	Gly	Asp	Gly	Lys
20					20					25					30
	Gly	Lys	Pro	Tyr	Gln	Gly	Ser	Gln	Glu	Leu	Thr	Leu	Thr	Val	Val
		,			35					40					45
	Lys	Gly	Gly	Pro	Leu	Pro	Phe	Ser	Tyr	Asp	Ile	Leu	Thr	Thr	Met
					50					55					60
25	Phe	Gln	Tyr	Gly	Așn	Arg	Ala	Phe	Val	Asn	Tyr	Pro	Glu	Asp	Ile
					65					70					75
	Pro	Asp	Ile	Phe	Lys	Gln	Thr	Cys	Ser	Gly	Pro	Asn	Gly	Gly	Tyr
					80					85					90
	Ser	Trp	Gln	Arg	Thr	Met	Thr	Tyr	Glu	Asp	Gly	Gly	Val	Cys	Thr
30					95					100					105
	Ala	Thr	Ser	Asn	Ile	Ser	Val	Val	Gly	Asp	Thr	Phe	Asn	Tyr	Asp
					110				•	115					120

PCT/US99/29405

Ile His Phe Met Gly Ala Asn Phe Pro Leu Asp Gly Pro Val Met Gln Lys Arg Thr Met Lys Trp Glu Pro Ser Thr Glu Ile Met Phe Glu Arg Asp Gly Met Leu Arg Gly Asp Ile Ala Met Ser Leu Leu Leu Lys Gly Gly His Tyr Arg Cys Asp Phe Glu Thr Ile Tyr Lys Pro Asn Lys Val Val Lys Met Pro Asp Tyr His Phe Val Asp His Cys Ile Glu Ile Thr Ser Gln Gln Asp Tyr Tyr Asn Val Val Glu Leu Thr Glu Val Ala Glu Ala Arg Tyr Ser Ser Leu Glu Lys Ile Gly Lys Ser Lys Ala <210> <211> <212> PRT <213> Discosoma sp. "magenta" <220> <223> amino acid sequence of dmFP592 <400> Met Ser Cys Ser Lys Asn Val Ile Lys Glu Phe Met Arg Phe Lys Val Arg Met Glu Gly Thr Val Asn Gly His Glu Phe Glu Ile Lys Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly His Cys Ser Val Lys 

	Leu	Met	Val	Thr	Lys	Gly	Gly	Pro	Leu	Pro	Phe	Ala	Phe	Asp	Ile
					50					55					60
	Leu	Ser	Pŗo	Gln	Phe	Gln	Tyr	Gly	Ser	Lys	Val	Tyr	Val	Lys	His
					65					70			-	,	75
5	Pro	Ala	Asp	Ile	Pro	Asp	Tyr	Lys	Lys	Leu	Ser	Phe	Pro	Glu	Gly
					80					85					90
	Phe	Lys	Trp	Glu	Arg	Val	Met	Asn	Phe	Glu	Asp	Gly	Gly	Val	Val
	<sub>#</sub> .	٠.			100					105					110
	Thr	Val	Ser	Gln	Asp	Ser	Ser	Leu	Lys	Asp	Gly	Cys	Phe	Ile	Tyr
10					115					120					125
	Glu	Val	Lys	Phe	Ile	Gly	Val	Asn	Phe	Pro	Ser	Asp	Gly	Pro	Val
	^				130					135					140
	Met	Gln	Arg	Arg	Thr	Arg	Gly	Trp	Glu	Ala	Ser	Ser	Glu	Arg	Leu
					145					150					155
15	Tyr	Pro	Arg	Asp	Gly	Val	Leu	Lys	Gly	Asp	Ile	His	Met	Ala	Leu
					160					165					170
	Arg	Leu	Glu	Gly	Gly	Gly	His	Tyr	Leu	Val	Glu	Phe	Lys	Ser	Ile
					175					180					185
	Tyr	Met	Val	Lys	Lys	Pro	Ser	Val	Gln	Leu	Pro	Gly	Tyr	Tyr	Tyr
20					190					195					200
	Val	Asp	Ser	Lys	Leu	Asp	Met	Thr	Ser	His	Asn	Glu	Asp	Tyr	Thr
					205					210					215
	Val	Val	Glu	Gln	Tyr	Glu	Lys	Thr	Gln	Gly	Arg	His	His	Pro	Phe
					220					225					230
25	Ile	Lys	Pro	Leu	Gln										
					235										

				٠,					
	International app	lication No.							
			PCT/US99/2940	)5					
A. CLASSIFICATION OF SUBJECT MATTER  IPC(7) :C12Q 1/68; C07K 14/435									
US CL :435/6, 69.1; 530/350 According to International Patent Classification (IPC) or to both national classification and IPC									
B. FIELDS SEARCHED									
Minimum documentation searched (classification system followed by classification symbols)  U.S.: 435/6, 69.1, 968; 530/350; 424/9.6, 436/172									
0.3 433/0, 07.1, 706; 330/330; 424/7.0, 430/1/2									
Documentat	ion searched other than minimum documentation to the	extent that such docu	ments are included	in the fields searched					
	ata base consulted during the international search (na e Extra Sheet.	me of data base and,	where practicable,	search terms used)					
C. DOC	UMENTS CONSIDERED TO BE RELEVANT								
Category*	Citation of document, with indication, where app	propriate, of the releva	ant passages	Relevant to claim No.					
***	The sequence diskette submitted with thus the references listed below were search, and not by a search of the SEC	* 1	1						
X, P	MATZ et al. Fluorescent protein Anthozoa species. Nature Biotechnolog No. 10, pages 969-973, entire docume		1-10						
X, P	DE 197 18 640 A1 (WIEDENMA document.	3-10							
		· · · · · · · · · · · · · · · · · · ·							
Further documents are listed in the continuation of Box C. See patent family annex.									
*A* document defining the general state of the art which is not considered to be of particular relevance  *A* document defining the general state of the art which is not considered to be of particular relevance  *A* document defining the general state of the art which is not considered to be of particular relevance									
*E* ca	e claimed invention cannot be red to involve an inventive step								
cit	cunent which may throw doubts on priority claim(s) or which is ad to establish the publication date of another citation or other scial reason (as specified)	ument is taken alone particular relevance; the involve an inventive	t is taken alone  sular relevance; the claimed invention cannot be  love an inventive step when the document is						
m.	cument referring to an oral disclosure, use, exhibition or other	ch documents, such combination the art							
the	cument published prior to the international filing date but later than priority date claimed		r of the same patent family						
Date of the actual completion of the international search  18 FEBRUARY 2000  Date of mailing of the international search report  2 MAR 2000									
Name and	mailing address of the ISA/US	Authorized officer							
Box PCT	ner of Patents and Trademarks	GABRIELE ELISABETH BOGAIST							
Facsimile N		Telephone No. (703) 308-0196							